Navigation Links
MannKind Submits NDA for AFRESA for Treatment of Diabetes
Date:3/16/2009

VALENCIA, Calif., March 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of AFRESA(R) (insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA(R) Inhaler for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia.

There are 23.6 million people in the United States, or 8% of the population, who have diabetes. Diabetes currently affects 246 million people worldwide and is expected to affect 380 million by 2025. Each year, a further 7 million people develop diabetes and 3.8 million people succumb to the disease.

AFRESA is an ultra rapid-acting insulin. It is a drug-device combination product, consisting of AFRESA Inhalation Powder pre-metered into single unit dose cartridges and the AFRESA Inhaler as the delivery device for oral inhalation. However, the feature that distinguishes AFRESA from all other insulin products is not the route of administration - it is the pharmacokinetic profile. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. AFRESA achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent or impaired in patients with diabetes.

The NDA submission is based on an extensive clinical program, involving 44 completed studies and five ongoing studies at the time of submission. The clinical program included over 5,300 patients. More than 2,450 subjects with type 1 or type 2 diabetes were randomly assig
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
2. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
3. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
6. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
7. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
8. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
9. MannKind to Present at the UBS Global Life Sciences Conference
10. MannKind Corporation Reports Second Quarter Financial Results
11. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer Experience ... Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines and ... of revenues. , Browse 152 market data tables, ... on “Service Quality Management (SQM) and Telco Customer Experience ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , SEATTLE, Aug. 11 Omeros Corporation ... trial of OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) product candidate. ... and an agent that causes pupil dilation (mydriasis), each ... Omeros, Phase 1/Phase 2 trial enrolled 61 ...
... QUEBEC CITY, Aug. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... focused on endocrinology and oncology, today reported financial and operating results ... 30, 2009. , , , Second Quarter ... poster presentations at the American Association of Cancer, ...
... ... at the Center for Orthopedics in Sheffield Village, Ohio, now offers OtisKnee® Custom Fit ... better implant fit and alignment -- and a faster return to an active lifestyle. ... Sheffield Village, ...
Cached Biology Technology:Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 7AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 8William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 2William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 3William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 4
(Date:12/22/2014)... SHELTON, Conn. , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile commerce ... consultant, Apollo Robbins for the 2015 International CES ... Apollo Robbins will be at the NXT-ID booth ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... six billion base pairs from the genome of one person ... the J. Craig Venter Institute (JCVI), along with collaborators at ... of California San Diego (UCSD), have published a genome sequence ... chromosomes that were inherited from each parent. ...
... The immune response is actively turned on to target and ... it is just as important to turn the immune system ... fruit fly Drosophila has served as a good model for ... pathways and mechanisms. Recent work shows that the flys immune ...
... The earliest domesticated pigs in Europe, which many archaeologists ... actually introduced from the Middle East by Stone Age ... international team led by archaeologists at Durham University, which ... the National Academies of Sciences USA, analysed mitochondrial DNA ...
Cached Biology News:First individual genome sequence published 2First individual genome sequence published 3First individual genome sequence published 4Pig study sheds new light on the colonisation of Europe by early farmers 2
... of cytoplasmic granules, is a key ... leukocytes (e.g. basophils, neutrophils, eosinophils, and ... these secretory granules contain many proinflammatory ... many proteases (Hallgren, 2001). Tryptase, a ...
... DNA gel stain was developed specifically for reduced ... for staining DNA in agarose or acrylamide gels. ... than ethidium bromide but SYBR Safe stain's detection ... SYBR Safe stain comes as a premixed solution ...
... enables scientists who do not have access to ... have their biological samples tested for the concentration ... as 1-2-3 Chose the analytes you ... the S&S antibody menu. Send your samples ...
... nucleic acid gel stain is an exceptionally ... fluorescence when bound to dsDNA and low background ... in gels using laser scanners or standard UV ... also found uses in capillary electrophoresis, real-time PCR ...
Biology Products: